Literature DB >> 10224474

Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses.

T Jakob1, P S Walker, A M Krieg, E von Stebut, M C Udey, J C Vogel.   

Abstract

BACKGROUND: Unmethylated CpG sequences in bacterial DNA act as adjuvants selectively inducing Th1 predominant immune responses during genetic vaccination or when used in conjunction with protein Ag. The precise mechanism of this adjuvant effect is unknown. Because dendritic cells (DC) are thought to be crucially involved in T cell priming and Th1/Th2 education during vaccination via skin, we characterized the effects of bacterial DNA and CpG-containing oligodeoxynucleotides (CpG ODN) on cutaneous DC. METHODS AND
RESULTS: Stimulation with CpG ODN 1826 (6 micrograms/ml) induced activation of immature Langerhans cell (LC)-like DC as determined by an increased expression of MHC class II and costimulatory molecules, loss of E-cadherin-mediated adhesion and increased ability to stimulate allogeneic T cells. Composition-matched control ODN 1911 lacking CpG sequences at equal concentrations was without effect. In comparison to LPS and ODN 1911, CpG ODN 1826 selectively stimulated DC to release large amounts of IL-12 (p40) and little IL-6 or TNF-alpha within 18 h and detectable levels of IL-12 p70 within 72 h. Stimulation with Escherichia coli DNA, but not calf thymus DNA, similarly induced DC maturation and IL-12 p40 production. Injection of CpG ODN into murine dermis induced enhanced expression of MHC class II and CD86 by LC in the overlying epidermis and intracytoplasmic IL-12 p40 accumulation in a subpopulation of activated LC.
CONCLUSION: Bacterial DNA and CpG ODN stimulate DC in vitro and in vivo and may preferentially elicit Th1-predominant immune responses because they can activate and mobilize DC, inducing them to produce IL-12.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10224474     DOI: 10.1159/000024163

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  10 in total

1.  Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.

Authors:  Klaus Zwiorek; Carole Bourquin; Julia Battiany; Gerhard Winter; Stefan Endres; Gunther Hartmann; Conrad Coester
Journal:  Pharm Res       Date:  2007-10-03       Impact factor: 4.200

2.  Role of Toll-like receptor 9 in Legionella pneumophila-induced interleukin-12 p40 production in bone marrow-derived dendritic cells and macrophages from permissive and nonpermissive mice.

Authors:  Cathy A Newton; Izabella Perkins; Raymond H Widen; Herman Friedman; Thomas W Klein
Journal:  Infect Immun       Date:  2006-10-23       Impact factor: 3.441

3.  Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godfroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

4.  Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.

Authors:  Anthony J Hickey; Jr-Shiuan Lin; Lawrence W Kummer; Frank M Szaba; Debra K Duso; Michael Tighe; Michelle A Parent; Stephen T Smiley
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

5.  Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.

Authors:  C M Leutenegger; F S Boretti; C N Mislin; J N Flynn; M Schroff; A Habel; C Junghans; S A Koenig-Merediz; B Sigrist; A Aubert; N C Pedersen; B Wittig; H Lutz
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godefroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

7.  Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3.

Authors:  Dirk J Lefeber; Barry Benaissa-Trouw; Johannes F G Vliegenthart; Johannis P Kamerling; Wouter T M Jansen; Kees Kraaijeveld; Harm Snippe
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

8.  Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.

Authors:  Emmanuel T Akporiaye; Deborah Bradley-Dunlop; Sandra J Gendler; Pinku Mukherjee; Cathy S Madsen; Tobias Hahn; David G Besselsen; Sharon M Dial; Haiyan Cui; Katrina Trevor
Journal:  Vaccine       Date:  2007-07-24       Impact factor: 3.641

9.  Induction of interleukin-12 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid, deviates CD4+ T cells from a Th2 to a Th1 response.

Authors:  Tae S Kim; Bok Y Kang; Daeho Cho; Seung H Kim
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

10.  MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.

Authors:  Ming Yang; Youyou Yan; Mingli Fang; Min Wan; Xiuli Wu; Xiaoling Zhang; Tiesuo Zhao; Hongfei Wei; Dandan Song; Liying Wang; Yongli Yu
Journal:  Int Immunopharmacol       Date:  2012-05-14       Impact factor: 4.932

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.